Jing Christine Ye

Jing Christine Ye is an Associate Professor at The University of Texas MD Anderson Cancer Center. Her research focuses on hematological malignancies, particularly multiple myeloma, with interests spanning immunotherapy, drug resistance mechanisms, and cancer pharmacology. She has contributed to pivotal clinical trials, including the MonumenTAL-1 study of talquetamab and the ADVANCE trial of carfilzomib-based regimens. Her recent work explores therapy-induced rapid drug resistance driven by genome chaos and polyploid giant cancer cells, as well as spatiotemporal analysis of tumor neoplastic evolution. She has published in leading journals including the New England Journal of Medicine, The Lancet Haematology, and Cancer Research, and has contributed to NCCN Clinical Practice Guidelines.